Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer. 1994

M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
Laboratory for Pathology, National Institute of Public Health and Environmental Protection (RIVM), Bilthoven, The Netherlands.

Because recent investigations showed that the use of isoniazid (INH) severely impaired the local immune reaction to intravesical bacillus Calmette-Guérin (BCG) in the bladder of guinea pigs, in this study the effect of INH in man has been investigated. Patients were treated with BCG with or without oral INH. The concentration of free INH in most urine samples of patients treated with BCG/INH was much higher (mean 38.0 +/- 60.9 micrograms INH/ml) than the minimal inhibitory concentration (MIC; 0.1 microgram INH/ml), suggesting at least a bacteriostatic potential of the INH present. However, in vitro studies showed that these urinary concentrations of INH did not kill BCG organisms effectively, even at a concentration of 150 micrograms/ml for 24 h. After the fifth and sixth BCG instillations a significant increase in the concentration of cytokines (IL2, IL6, IL8 and TNFa), IgG and IgA antibodies to BCG and the number of leukocytes in urine was observed. The leukocytes mainly consisted of granulocytes, besides monocytes/macrophages and, in lower amounts, T- and B-lymphocytes and natural killer (NK) cells. The absolute number of granulocytes and the concentration of IgG antibodies after BCG instillation were significantly suppressed by INH, whereas INH appeared to have no effect on the urinary cytokine and IgA antibody concentrations or the total number and phenotype of the leukocytes present. In conclusion, the results of this study indicate that INH does not impair the local immunological stimulation after BCG instillation in man as severely as was observed in the guinea pig and it may be expected that INH does not impair the antitumor efficacy of BCG.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D007962 Leukocytes White blood cells. These include granular leukocytes (BASOPHILS; EOSINOPHILS; and NEUTROPHILS) as well as non-granular leukocytes (LYMPHOCYTES and MONOCYTES). Blood Cells, White,Blood Corpuscles, White,White Blood Cells,White Blood Corpuscles,Blood Cell, White,Blood Corpuscle, White,Corpuscle, White Blood,Corpuscles, White Blood,Leukocyte,White Blood Cell,White Blood Corpuscle
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002452 Cell Count The number of CELLS of a specific kind, usually measured per unit volume or area of sample. Cell Density,Cell Number,Cell Counts,Cell Densities,Cell Numbers,Count, Cell,Counts, Cell,Densities, Cell,Density, Cell,Number, Cell,Numbers, Cell

Related Publications

M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
September 1998, Hinyokika kiyo. Acta urologica Japonica,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
June 1998, British journal of urology,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
January 1999, Clinical and experimental immunology,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
April 1994, Journal of clinical pharmacy and therapeutics,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
November 1996, British journal of urology,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
January 1997, Urological research,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
February 1988, The Journal of urology,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
January 1988, Progress in clinical and biological research,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
August 1992, Urology,
M J Stassar, and P D Vegt, and P A Steerenberg, and A P van der Meijden, and H D Meiring, and M Dessens-Kroon, and H G Geertzen, and W den Otter
January 1996, International journal of urology : official journal of the Japanese Urological Association,
Copied contents to your clipboard!